Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Saniona AB Snapshot | 6 | 1 |
| Saniona AB Overview | 6 | 1 |
| Key Information | 6 | 1 |
| Key Facts | 6 | 1 |
| Saniona AB Research and Development Overview | 7 | 3 |
| Key Therapeutic Areas | 7 | 3 |
| Saniona AB Pipeline Review | 10 | 5 |
| Pipeline Products by Stage of Development | 10 | 1 |
| Pipeline Products Monotherapy | 11 | 1 |
| Pipeline Products Combination Treatment Modalities | 12 | 1 |
| Pipeline Products Out-Licensed Products | 13 | 1 |
| Out-Licensed Products/Combination Treatment Modalities | 14 | 1 |
| Saniona AB Pipeline Products Glance | 15 | 4 |
| Saniona AB Clinical Stage Pipeline Products | 15 | 1 |
| Phase II Products/Combination Treatment Modalities | 15 | 1 |
| Phase I Products/Combination Treatment Modalities | 16 | 1 |
| Saniona AB Early Stage Pipeline Products | 17 | 1 |
| Preclinical Products/Combination Treatment Modalities | 17 | 1 |
| Discovery Products/Combination Treatment Modalities | 18 | 1 |
| Saniona AB Drug Profiles | 19 | 25 |
| (metoprolol + tesofensine) | 19 | 1 |
| Product Description | 19 | 1 |
| Mechanism of Action | 19 | 1 |
| R&D Progress | 19 | 2 |
| NS-2359 | 21 | 1 |
| Product Description | 21 | 1 |
| Mechanism of Action | 21 | 1 |
| R&D Progress | 21 | 2 |
| tesofensine | 23 | 1 |
| Product Description | 23 | 1 |
| Mechanism of Action | 23 | 1 |
| R&D Progress | 23 | 3 |
| AN-721 | 26 | 1 |
| Product Description | 26 | 1 |
| Mechanism of Action | 26 | 1 |
| R&D Progress | 26 | 1 |
| AN-788 | 27 | 1 |
| Product Description | 27 | 1 |
| Mechanism of Action | 27 | 1 |
| R&D Progress | 27 | 1 |
| AN-346 | 28 | 1 |
| Product Description | 28 | 1 |
| Mechanism of Action | 28 | 1 |
| R&D Progress | 28 | 1 |
| AN-470 | 29 | 1 |
| Product Description | 29 | 1 |
| Mechanism of Action | 29 | 1 |
| R&D Progress | 29 | 2 |
| AN-761 | 31 | 1 |
| Product Description | 31 | 1 |
| Mechanism of Action | 31 | 1 |
| R&D Progress | 31 | 1 |
| NS-9283 | 32 | 1 |
| Product Description | 32 | 1 |
| Mechanism of Action | 32 | 1 |
| R&D Progress | 32 | 2 |
| Small Molecule to Agonize GABAA Alpha 2 and Alpha 3 for Neuropathic Pain | 34 | 1 |
| Product Description | 34 | 1 |
| Mechanism of Action | 34 | 1 |
| R&D Progress | 34 | 1 |
| Small Molecules to Agonize nAChR Alpha7 for Pain and Alzheimer's Disease | 35 | 1 |
| Product Description | 35 | 1 |
| Mechanism of Action | 35 | 1 |
| R&D Progress | 35 | 1 |
| Small Molecule to Activate Kv7.2 and Kv7.3 Channels for Epilepsy and Pain | 36 | 1 |
| Product Description | 36 | 1 |
| Mechanism of Action | 36 | 1 |
| R&D Progress | 36 | 1 |
| Small Molecule to Activate TREK for Pain | 37 | 1 |
| Product Description | 37 | 1 |
| Mechanism of Action | 37 | 1 |
| R&D Progress | 37 | 1 |
| Small Molecule to Agonize GABA Alpha 4 Delta Receptor for Sleep Disorders, Stress and Autism | 38 | 1 |
| Product Description | 38 | 1 |
| Mechanism of Action | 38 | 1 |
| R&D Progress | 38 | 1 |
| Small Molecule to Agonize GABAA Receptor Subunit Alpha-4 and Gamma for Epilepsy | 39 | 1 |
| Product Description | 39 | 1 |
| Mechanism of Action | 39 | 1 |
| R&D Progress | 39 | 1 |
| Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism | 40 | 1 |
| Product Description | 40 | 1 |
| Mechanism of Action | 40 | 1 |
| R&D Progress | 40 | 1 |
| Small Molecule to Agonize nAChR Alpha6 for Parkinson's Disease | 41 | 1 |
| Product Description | 41 | 1 |
| Mechanism of Action | 41 | 1 |
| R&D Progress | 41 | 1 |
| Small Molecule to Block TREK for Depression | 42 | 1 |
| Product Description | 42 | 1 |
| Mechanism of Action | 42 | 1 |
| R&D Progress | 42 | 1 |
| Small Molecule to Inhibit Monoamine Reuptake for Pain | 43 | 1 |
| Product Description | 43 | 1 |
| Mechanism of Action | 43 | 1 |
| R&D Progress | 43 | 1 |
| Saniona AB Pipeline Analysis | 44 | 6 |
| Saniona AB Pipeline Products by Target | 44 | 2 |
| Saniona AB Pipeline Products by Route of Administration | 46 | 1 |
| Saniona AB Pipeline Products by Molecule Type | 47 | 1 |
| Saniona AB Pipeline Products by Mechanism of Action | 48 | 2 |
| Saniona AB Recent Pipeline Updates | 50 | 1 |
| Saniona AB Dormant Projects | 51 | 1 |
| Saniona AB Discontinued Pipeline Products | 52 | 1 |
| Discontinued Pipeline Product Profiles | 52 | 1 |
| NS-2359 | 52 | 1 |
| tesofensine | 52 | 1 |
| Saniona AB Locations And Subsidiaries | 53 | 1 |
| Head Office | 53 | 1 |
| Appendix | 54 | 2 |
| Methodology | 54 | 1 |
| Coverage | 54 | 1 |
| Secondary Research | 54 | 1 |
| Primary Research | 54 | 1 |
| Expert Panel Validation | 54 | 1 |
| Contact Us | 54 | 1 |
| Disclaimer | 55 | 1 |